This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/827,302	09/827,302 04/05/2001		Ellis L. Kline	13395-0101 (44448-256971)	4139
23594	7590	06/20/2002			
JOHN S. PRATT KILPATRICK STOCKTON LLP 1100 PEACHTREE			EXAMINER		
				MELLER, MICHAEL V	
SUITE 2800 ATLANTA,		100		ART UNIT	PAPER NUMBER
AILANIA,	GA 303			1651	2
				DATE MAILED: 06/20/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)		
	Office Action Summary	09/827,302	KLINE, ELLIS L.		
	omoc nousin cumuary	Examin r	Art Unit		
	The MAILING DATE of this communicati n ap	Michael V. Meller	1651		
Period fo		pears on the cover sheet with	are correspondence address		
THE N - Exten after: - If the - If NO - Failur - Any o	DRTENED STATUTORY PERIOD FOR REPI MAILING DATE OF THIS COMMUNICATION sions of time may be available under the provisions of 37 CFR 1 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a re period for reply is specified above, the maximum statutory period e to reply within the set or extended period for reply will, by statu- apply received by the Office later than three months after the mailing d patent term adjustment. See 37 CFR 1.704(b).	. 136(a). In no event, however, may a reply ply within the statutory minimum of thirty (3 d will apply and will expire SIX (6) MONTH te, cause the application to become ABAN	y be timely filed 30) days will be considered timely. S from the mailing date of this communication. IDONED (35 U.S.C. § 133).		
1)⊠	Responsive to communication(s) filed on 16	April 2002 .			
2a)⊠		his action is non-final.			
3)□	·				
Dispositi	on of Claims				
4) 🖂	Claim(s) 1,2 and 4-11 is/are pending in the a	pplication.			
4	4a) Of the above claim(s) <u>10 and 11</u> is/are wit	hdrawn from consideration.			
5)	Claim(s) is/are allowed.				
6)⊠	Claim(s) <u>1, 2 and 4-9</u> is/are rejected.				
7)	Claim(s) is/are objected to.				
8)□	Claim(s) are subject to restriction and/	or election requirement.			
Application	on Papers				
9)[] 7	The specification is objected to by the Examin	er.			
10)[] 7	The drawing(s) filed on is/are: a)☐ acc	epted or b) objected to by the	Examiner.		
	Applicant may not request that any objection to t		, ,		
11)[1	he proposed drawing correction filed on		approved by the Examiner.		
	If approved, corrected drawings are required in r	• •			
	The oath or declaration is objected to by the E	xaminer.			
	nder 35 U.S.C. §§ 119 and 120				
	Acknowledgment is made of a claim for foreig	gn priority under 35 U.S.C. § 1	19(a)-(d) or (f).		
,-	☐ All b)☐ Some * c)☐ None of:				
	1. Certified copies of the priority documents have been received.				
2. Certified copies of the priority documents have been received in Application No					
	3. Copies of the certified copies of the pricapplication from the International B ee the attached detailed Office action for a lis	ureau (PCT Rule 17.2(a)).	•		
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment	·	•			
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Info	mmary (PTO-413) Paper No(s) nmal Patent Application (PTO-152)		

Application/Control Number: 09/827,302		Page 2
Art Unit: 1651		

DETAILED ACTION

Election/Restrictions

Applicant's election with traverse of solid tumors in Paper No. 6 is acknowledged. The traversal is on the ground(s) that it is not an undue burden on the examiner to search all of the claimed species. This is not found persuasive because applicant has provided no evidence or identified such evidence of record showing the species to be obvious variants or clearly admit on the record that this is the case as stated in the previous Office action.

Claims 10 and 11 remain withdrawn from further consideration by the examiner as being drawn to a non elected invention.

The requirement is still deemed proper and is therefore made FINAL.

Claim Rejections - 35 USC § 103

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 1, 2 and 4-9 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Watkins, Jr. et al. taken with Green et al. for the reasons of record and for the reasons which follow.

Application/Control Number:	Page 3
09/827,302	_
Art Unit: 1651	

Applicant has argued that Watkins teaches treating cells outside of the body and then injecting them into a patient. Applicant argues that it would not have been obvious to practice the claimed invention.

Applicant has claimed a method for treating a human with a neoplasm, comprising administering to the human with the neoplasm an effective amount of neurominidase. Watkins clearly teaches that neuraminidase is administered to humans with a neoplasm. This is all the claim requires. Thus, the claimed invention is obvious over the cited references.

Green was cited only to show that phenol-saline is a common physiologically-acceptable carrier for compositions, such as finely divided microparticles of tyrosine. It was cited as a general teaching to show the wide use of phenol saline as a solution for injection of biological materials into the body.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

Application/Control Number:	Page 4
09/827,302	 _
Art Unit: 1651	,

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael V. Meller whose telephone number is 703-308-4230. The examiner can normally be reached on Monday thru Friday: 9:00am-5:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached on 703-308-4743. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-0294 for regular communications and 703-308-0294 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Michael V. Meller Examiner Art Unit 1651

MVM June 19, 2002